Solicitation for Public Comments on Section 209 of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act, 16372 [2020-06047]
Download as PDF
<![CDATA[
16372
Federal Register / Vol. 85, No. 56 / Monday, March 23, 2020 / Notices
person and is not binding on FDA or the
public. You can use an alternative
approach if it satisfies the requirements
of the applicable statutes and
regulations.
III. Paperwork Reduction Act of 1995
This guidance refers to previously
approved FDA collections of
information. These collections of
information are subject to review by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501–3521). The
collection of information for ‘‘Current
Good Manufacturing Practices for
Finished Pharmaceuticals and Medical
Gases’’ has been approved under OMB
control number 0910–0139. The
collection of information for
‘‘Postmarketing Adverse Drug
Experience Reporting’’ has been
approved under OMB control number
0910–0230. The collection of
information for ‘‘MedWatch: Adverse
Event and Product Experience Reporting
System (Paper-Based)’’ has been
approved under OMB control number
0910–0291. The collection of
information for ‘‘Format and Content
Requirements for Over-the-Counter Drug
Product Labeling’’ has been approved
under OMB control number 0910–0340.
The collection of information for ‘‘FDA
Adverse Event and Products Experience
Reports; Electronic Submissions’’ has
been approved under OMB control
number 0910–0645. The collection of
information for ‘‘Adverse Event
Reporting for Outsourcing Facilities
Under Section 503B of the Federal
Food, Drug, and Cosmetic Act’’ has been
approved under OMB control number
0910–0800.
IV. Electronic Access
Persons with access to the internet
may obtain the guidance at either
https://www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs or https://
www.regulations.gov.
Dated: March 17, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020–05959 Filed 3–20–20; 8:45 am]
BILLING CODE 4164–01–P
jbell on DSKJLSW7X2PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Solicitation for Public Comments on
Section 209 of the Pandemic and AllHazards Preparedness and Advancing
Innovation Act
Office of Infectious Disease and
HIV/AIDS Policy, Office of the Assistant
AGENCY:
VerDate Sep<11>2014
17:26 Mar 20, 2020
Jkt 250001
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Request for public comment.
The Office of the Assistant
Secretary for Health in the Department
of Health and Human Services seeks
public comment regarding Section 209
of the Pandemic and All-Hazards
Preparedness and Advancing Innovation
Act.
Congress passed the Pandemic and
All-Hazards Preparedness and
Advancing Innovation Act (PAHPAIA)
in June 2019. Section 209 of this
legislation states that the Secretary of
Health and Human Services shall
submit to Congress a report containing
recommendations related to maintaining
an adequate national blood supply. The
legislation poses four specific questions
regarding the adequacy of the national
blood supply. HHS welcomes any
public feedback related to how these
questions should be addressed and/or
potential solutions. The set of questions
is available in the SUPPLEMENTARY
INFORMATION section below.
DATES: To be assured consideration,
electronic or written/paper comments
must be submitted no later than
midnight Eastern Standard Time (EST)
on April 22, 2020.
ADDRESSES: Individuals are encouraged
to submit responses electronically to
ACBTSA@hhs.gov. Please indicate ‘‘RFI
RESPONSE’’ in the subject line of your
email. Written responses should be
addressed to: U.S. Department of Health
and Human Services, Mary E. Switzer
Building, 330 C Street SW, Room L600,
Washington, DC 20024 Attn: ACBTSA–
PAHPAIA Sec. 209. Mailed paper
submissions and electronic submissions
received after the deadline will not be
reviewed. Responses to this notice are
not offers and cannot be accepted by the
federal government to form a binding
contract or issue a grant.
FOR FURTHER INFORMATION CONTACT: Mr.
James Berger, Designated Federal
Officer, Office of Infectious Disease and
HIV/AIDS Policy, (202) 795–7608.
SUPPLEMENTARY INFORMATION:
(1) Challenges associated with the
continuous recruitment of blood donors
(including those newly eligible to
donate);
(2) Ensuring the adequacy of the
blood supply in the case of public
health emergencies;
(3) Implementation of the transfusion
transmission monitoring system; and
(4) Other measures to promote safety
and innovation, such as the
development, use, or implementation of
new technologies, processes, and
SUMMARY:
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
procedures to improve the safety and
reliability of the blood supply.
Dated: March 11, 2020.
James J. Berger,
Senior Advisor for Blood and Tissue Policy,
Office of Infectious Disease and HIV/AIDS
Policy.
[FR Doc. 2020–06047 Filed 3–20–20; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Inspector General
[OIG–1810–N]
Statement of Organization, Functions,
and Delegations of Authority
Office of Inspector General
(OIG), HHS.
ACTION: Notice.
AGENCY:
This notice replaces all
language in Part Q (Office of the
Secretary) of the Statement of
Organization, Functions, and
Delegations of Authority for the
Department of Health and Human
Services (HHS or the Department),
Office of Inspector General (OIG),
(published March 15, 2016).
SUPPLEMENTARY INFORMATION: The
Statement of Organization, Functions,
and Delegations of Authority conforms
to and carries out the statutory
requirements for operating OIG. The
organizational changes reflected in this
notice are primarily to realign the
functions within OIG to better reflect
the current work environment and
priorities and to more clearly delineate
responsibilities for the various activities
within OIG’s offices.
OIG was established by law as an
independent and objective oversight
unit of the Department to carry out the
mission of preventing fraud and abuse
and promoting economy, efficiency, and
effectiveness of HHS programs and
operations. In furtherance of this
mission, the organization:
• Conducts and supervises audits,
investigations, evaluations, and
inspections relating to HHS programs
and operations;
• identifies systemic weaknesses
giving rise to opportunities for fraud
and abuse in HHS programs and
operations and makes recommendations
to prevent their recurrence;
• leads and coordinates activities to
prevent and detect fraud and abuse in
HHS programs and operations;
• detects wrongdoers and abusers of
HHS programs and beneficiaries so
appropriate remedies may be brought to
SUMMARY:
E:\FR\FM\23MRN1.SGM
23MRN1
]]>Agencies
[Federal Register Volume 85, Number 56 (Monday, March 23, 2020)]
[Notices]
[Page 16372]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-06047]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Solicitation for Public Comments on Section 209 of the Pandemic
and All-Hazards Preparedness and Advancing Innovation Act
AGENCY: Office of Infectious Disease and HIV/AIDS Policy, Office of the
Assistant Secretary for Health, Office of the Secretary, Department of
Health and Human Services.
ACTION: Request for public comment.
-----------------------------------------------------------------------
SUMMARY: The Office of the Assistant Secretary for Health in the
Department of Health and Human Services seeks public comment regarding
Section 209 of the Pandemic and All-Hazards Preparedness and Advancing
Innovation Act.
Congress passed the Pandemic and All-Hazards Preparedness and
Advancing Innovation Act (PAHPAIA) in June 2019. Section 209 of this
legislation states that the Secretary of Health and Human Services
shall submit to Congress a report containing recommendations related to
maintaining an adequate national blood supply. The legislation poses
four specific questions regarding the adequacy of the national blood
supply. HHS welcomes any public feedback related to how these questions
should be addressed and/or potential solutions. The set of questions is
available in the SUPPLEMENTARY INFORMATION section below.
DATES: To be assured consideration, electronic or written/paper
comments must be submitted no later than midnight Eastern Standard Time
(EST) on April 22, 2020.
ADDRESSES: Individuals are encouraged to submit responses
electronically to [email protected]. Please indicate ``RFI RESPONSE'' in
the subject line of your email. Written responses should be addressed
to: U.S. Department of Health and Human Services, Mary E. Switzer
Building, 330 C Street SW, Room L600, Washington, DC 20024 Attn:
ACBTSA-PAHPAIA Sec. 209. Mailed paper submissions and electronic
submissions received after the deadline will not be reviewed. Responses
to this notice are not offers and cannot be accepted by the federal
government to form a binding contract or issue a grant.
FOR FURTHER INFORMATION CONTACT: Mr. James Berger, Designated Federal
Officer, Office of Infectious Disease and HIV/AIDS Policy, (202) 795-
7608.
SUPPLEMENTARY INFORMATION:
(1) Challenges associated with the continuous recruitment of blood
donors (including those newly eligible to donate);
(2) Ensuring the adequacy of the blood supply in the case of public
health emergencies;
(3) Implementation of the transfusion transmission monitoring
system; and
(4) Other measures to promote safety and innovation, such as the
development, use, or implementation of new technologies, processes, and
procedures to improve the safety and reliability of the blood supply.
Dated: March 11, 2020.
James J. Berger,
Senior Advisor for Blood and Tissue Policy, Office of Infectious
Disease and HIV/AIDS Policy.
[FR Doc. 2020-06047 Filed 3-20-20; 8:45 am]
BILLING CODE 4150-28-P
